Provided by Tiger Fintech (Singapore) Pte. Ltd.

CervoMed

9.05
+2.6140.53%
Pre-market: 8.83-0.2200-2.43%04:43 EDT
Volume:20.04M
Turnover:170.60M
Market Cap:74.70M
PE:-5.65
High:9.51
Open:7.07
Low:7.00
Close:6.44
Loading ...

Company Profile

Company Name:
CervoMed
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
8
Office Location:
20 Park Plaza,Suite 424,Boston,Massachusetts,United States
Zip Code:
02116
Fax:
- -
Introduction:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
David G. Kalergis
Chairman of the Board
Robert J. Cobuzzi, Jr.
Director,President and Chief Executive Officer
Alan Levin
Director
Jane H. Hollingsworth
Director
Mark T. Giles
Director
Robert Adams
Director

Shareholders

Name
Position
Robert J. Cobuzzi, Jr.
Director,President and Chief Executive Officer
William K. Hornung
Chief Financial Officer
Christopher D. Galloway
Chief Medical Officer
William R. Elder
General Counsel,Corporate Secretary